The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders

Internal Medicine Journal

Volumn 46, Issue 1, 2016, Pages 17-28

  Rebeiro, P ^a   Moore, J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Autoimmune disorder; Autologous stem cell transplant

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON;

AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CD4+ T LYMPHOCYTE; CELL REGENERATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CROHN DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; EXPANDED DISABILITY STATUS SCALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MODIFIED RODNAN TOTAL SKIN THICKNESS SCORE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T CELL DEPLETION; VISUAL ANALOG SCALE; ANIMAL; AUTOIMMUNE DISEASES; AUTOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84969369438     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12944     Document Type: Review

References (76)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-26.
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
4. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997; 99: 9-22.
5. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768-84.
6. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-12.
7. Snowden JA, Nivison-Smith I, Biggs JC, Brooks PM. Risk taking in patients with rheumatoid arthritis: are the risks of haemopoietic stem cell transplantation acceptable? Rheumatology 1999; 38: 321-4.
8. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24years. J Rheumatol 1997; 24: 1061-5.
9. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995; 22: 2100-2.
10. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788-92.
11. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
12. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284-92.
13. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997; 36: 390-2.
14. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770-90.
15. van Bekkum DW. BMT in experimental autoimmune diseases. Bone Marrow Transplant 1993; 11: 183-7.
16. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42: 2286-92.
17. Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005; 35: 869-79.
18. Burt RK, Burns W, Ruvolo P, Fischer A, Shiao C, Guimaraes A et al. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 1995; 41: 526-31.
19. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-16.
20. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014; 124: 1168-72.
21. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-23.
22. Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005; 52: 1555-63.
23. Baraut J, Grigore EI, Jean-Louis F, Khelifa SH, Durand C, Verrecchia F et al. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 2014; 49: 349-54.
24. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55.
25. Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
26. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
27. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-39.
28. Daumer M, Griffith LM, Meister W, Nash RA, Wolinsky JS. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Mult Scler 2006; 12: 174-9.
29. Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000; 247: 376-82.
30. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7: 626-36.
31. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30.
32. Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010; 16: 685-93.
33. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012; 18: 835-42.
34. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364-72.
35. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373-8.
36. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006; 20: 485-9.
37. Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84: 276-81.
38. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-53.
39. Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kartashov AV et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 2012; 40: 892-8.
40. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814-23.
41. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 2014; 85: 1116-21.
42. Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 2015; 313: 275-84.
43. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015; 72: 159-69.
44. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW et al. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2012; 18: 1471-8.
45. Muraro P, Pasquini M, Atkins H, Bowen J, Farge D, Fassas A et al. Long term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Centre for International Blood and Marrow Research (CIBMTR) and from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2013; 48 Abstract 71: pS1.
46. Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015; 84: 981-8.
47. Tyndall AC, Black J, Finke J, Winkler R, Mertlesmann HHP et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349.
48. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116-24.
49. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-96.
50. Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008; 67: 98-104.
51. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.[comment]. Ann Rheum Dis 2001; 60: 577-84.
52. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974-81.
53. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-39.
54. Moore J, Englert H, Furlong T, Poon T, Milliken S, Ma D. Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Bone Marrow Transplant 2012; 47: 1486-7.
55. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.
56. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8.
57. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602-10.
58. Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziak P, Bucha J et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116: 6123-32.
59. Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W, Schmidt C et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 2012; 36: 725-35.
60. Snowden JA, Ansari A, Sachchithanantham S, Jackson G, Thompson N, Lobo A et al. Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis. QJM 2014; 107: 871-7.
61. Hawkey C, the ASTIC Trialists. Autologous haemopoietic stem cell transplantation for resistant Crohn's disease: Final RCT efficacy data: sponsored by the Autoimmune Diseases Working Party and the European Crohn's and Colitis Organisation. Bone Marrow Transplant 2014; 49(S1-5Abstract 6): pS2.
62. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-76.
63. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Krol M et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011; 46: 562-6.
64. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 168-76.
65. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301-9.
66. Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 241-7.
67. Moore J, Milliken S, Snowden J, Brooks P, Biggs J, Englert H et al. Safety and benefit of autologous stem cell transplant for auto-immune diseases: 15years experience from a single institution. Poster presentation. In: HAA Conference. Sydney:; 2011.
68. Snowden JA, Akil M, Kiely DG. Improving safety in autologous HSCT for systemic sclerosis. Lancet 2013; 381: 1081-3.
69. Australian Bureau of Statistics. Survey of Disability. Canberra: Ageing and Carers; 2012.
70. Multiple Sclerosis Research Australia. Economic Impact of Multiple Sclerosis in Australian. Sydney: MS Longitudinal Study; 2010.
71. Bernatsky S, Hudson M, Panopalis P, Clarke AE, Pope J, Leclercq S et al. The cost of systemic sclerosis. Arthritis Rheum 2009; 61: 119-23.
72. Gordon R, Thompson C, Carolan J, Eckstein G, Rostron C. A Costing Study of Blood and Marrow Transplantation Services in NSW: Final Report. Centre for Health Service Development: University of Wollongong; 2009.
73. Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 2010; 45: 1014-21.
74. Tichelli A, Rovo A. Fertility issues following hematopoietic stem cell transplantation. Expert Rev Hematol 2013; 6: 375-88.
75. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-52.
76. Snarski E, Snowden JA, Oliveira MC, Simoes B, Badoglio M, Carlson K et al. Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant 2015; 50: 216-20.